These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29966456)

  • 1. Managing myeloma with limited resources in the era of novel drugs.
    Dimopoulos MA; Kastritis E
    Leuk Lymphoma; 2018 Oct; 59(10):2269-2270. PubMed ID: 29966456
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelosuppression associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Miceli T; Colson K; Gavino M; Lilleby K;
    Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):13-20. PubMed ID: 18490253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Smith LC; Bertolotti P; Curran K; Jenkins B;
    Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):37-52. PubMed ID: 18490256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project.
    Blade J; Calleja MÁ; Lahuerta JJ; Poveda JL; de Paz HD; Lizán L
    BMJ Open; 2018 Feb; 8(2):e018850. PubMed ID: 29472263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.
    Takamatsu H; Honda S; Miyamoto T; Yokoyama K; Hagiwara S; Ito T; Tomita N; Iida S; Iwasaki T; Sakamaki H; Suzuki R; Sunami K
    Cancer Sci; 2015 Feb; 106(2):179-85. PubMed ID: 25530023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Kumar S; Paiva B; Anderson KC; Durie B; Landgren O; Moreau P; Munshi N; Lonial S; Bladé J; Mateos MV; Dimopoulos M; Kastritis E; Boccadoro M; Orlowski R; Goldschmidt H; Spencer A; Hou J; Chng WJ; Usmani SZ; Zamagni E; Shimizu K; Jagannath S; Johnsen HE; Terpos E; Reiman A; Kyle RA; Sonneveld P; Richardson PG; McCarthy P; Ludwig H; Chen W; Cavo M; Harousseau JL; Lentzsch S; Hillengass J; Palumbo A; Orfao A; Rajkumar SV; Miguel JS; Avet-Loiseau H
    Lancet Oncol; 2016 Aug; 17(8):e328-e346. PubMed ID: 27511158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
    Hussein MA; Vrionis FD; Allison R; Berenson J; Berven S; Erdem E; Giralt S; Jagannath S; Kyle RA; LeGrand S; Pflugmacher R; Raje N; Rajkumar SV; Randall RL; Roodman D; Siegel D; Vescio R; Zonder J; Durie BG;
    Leukemia; 2008 Aug; 22(8):1479-84. PubMed ID: 18509352
    [No Abstract]   [Full Text] [Related]  

  • 8. Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Rome S; Doss D; Miller K; Westphal J;
    Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):21-8. PubMed ID: 18490254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma.
    Lokhorst H; Einsele H; Vesole D; Bruno B; San Miguel J; Pérez-Simon JA; Kröger N; Moreau P; Gahrton G; Gasparetto C; Giralt S; Bensinger W;
    J Clin Oncol; 2010 Oct; 28(29):4521-30. PubMed ID: 20697091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
    Faiman B; Bilotti E; Mangan PA; Rogers K;
    Clin J Oncol Nurs; 2008 Jun; 12(3 Suppl):53-63. PubMed ID: 18490257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of
    Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
    Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
    Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS; Tombler ER; Stadtmauer E; Jagannath S; Anderson KC;
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):356-69. PubMed ID: 25066040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
    Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
    Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
    van de Donk NW; Lokhorst HM; Dimopoulos M; Cavo M; Morgan G; Einsele H; Kropff M; Schey S; Avet-Loiseau H; Ludwig H; Goldschmidt H; Sonneveld P; Johnsen HE; Bladé J; San-Miguel JF; Palumbo A
    Cancer Treat Rev; 2011 Jun; 37(4):266-83. PubMed ID: 20863623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma in the era of novel agents.
    Dimopoulos MA; Attal M
    Semin Hematol; 2009 Apr; 46(2):107-9. PubMed ID: 19389493
    [No Abstract]   [Full Text] [Related]  

  • 17. The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.
    Schots R; Delforge M; André M; Bries G; Caers J; Demuynck H; De Prijck B; De Samblanx H; Kentos A; Meuleman N; Offner F; Vekemans MC; Vande Broek I; Van Droogenbroeck J; Van de Vanelde A; Wu KL; Doyen C;
    Acta Clin Belg; 2010; 65(4):252-64. PubMed ID: 20954465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs in multiple myeloma.
    Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents.
    Zagouri F; Kastritis E; Symeonidis AS; Giannakoulas N; Katodritou E; Delimpasi S; Repousis P; Terpos E; Dimopoulos MA;
    Eur J Haematol; 2014 Apr; 92(4):308-12. PubMed ID: 24460646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical benefit and regimen selection for patients with newly-diagnosed multiple myeloma in the era of novel agents].
    Geng CY; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):297-8. PubMed ID: 23668199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.